Projects funded by the NCN

Information on the principal investigator and host institution

Information of the project and the call

Keywords

Equipment

Delete all

Novel peptide inhibitors of dipeptidyl peptidase IV (DPP IV) as novel approach for diabetes type 2 and inflammatory bowel diseases treatment

2013/11/N/NZ7/02354

Keywords:

diabetes type 2 inflammatory bowel diseases dipeptidyl peptidase IV inhibitor anti-diabetic drug anti-inflammatory drug

Descriptors:

  • NZ7_14: Pharmacy, pharmacotherapy, pharmacology

Panel:

NZ7 - Diagnostic tools, therapies and public health: public health, epidemiology, environmental health risks and occupational medicine, medical ethics, drug discovery and therapies, pharmacology

Host institution :

Uniwersytet Medyczny w Łodzi, Wydział Lekarski

woj. łódzkie

Other projects carried out by the institution 

Principal investigator (from the host institution):

Maciej Sałaga 

Number of co-investigators in the project: 3

Call: PRELUDIUM 6 - announced on 2013-09-16

Amount awarded: 135 187 PLN

Project start date (Y-m-d): 2014-09-22

Project end date (Y-m-d): 2018-09-21

Project duration:: 48 months (the same as in the proposal)

Project status: Project settled

Information in the final report

  • Publication in academic press/journals (2)
  • Articles in post-conference publications (1)
  1. New Peptide Inhibitor of Dipeptidyl Peptidase IV, EMDB-1 Extends the Half-Life of GLP-2 and Attenuates Colitis in Mice after Topical Administration
    Authors:
    Maciej Sałaga, Anna Mokrowiecka, Marta Zielińska, Ewa Małecka-Panas, Radzisław Kordek, Elżbieta Kamysz, Jakub Fichna
    Academic press:
    Journal of Pharmacology and Experimental Therapeutics (rok: 2017, tom: 363, strony: 92-103), Wydawca: American Society for Pharmacology and Experimental Therapeutics
    Status:
    Published
    DOI:
    10.1124/jpet.117.242586 - link to the publication
  2. Novel peptide inhibitor of dipeptidyl peptidase IV (Tyr-Pro-D-Ala-NH2) with anti-inflammatory activity in the mouse models of colitis
    Authors:
    Maciej Sałaga, Agata Binienda, Piotr Drączkowski, Piotr Kosson, Radzisław Kordek, Krzysztof Jóżwiak, Jakub Fichna
    Academic press:
    Peptides (rok: 2018, tom: 108, strony: 34-45), Wydawca: Elsevier
    Status:
    Published
    DOI:
    10.1016/J.PEPTIDES.2018.08.011 - link to the publication
  1. NEW, PEPTIDE INHIBITOR OF DIPEPTIDYL PEPTIDASE IV, EMDB-1 ATTENUATES COLITIS IN MICE AFTER TOPICAL ADMINISTRATION
    Authors:
    Maciej Salaga, Paula Mosinska, Hubert Zatorski, Marta Zielinska, Jakub Fichna
    Conference:
    24th United European Gastroenterology Week (rok: 2016, ), Wydawca: United European Gastroenterology
    Data:
    konferencja 15-19.10
    Status:
    Published

O Narodowym Centrum Nauki

Finansowanie nauki

Współpraca zagraniczna

Centrum prasowe

Deklaracja dostępności
Przetwarzanie danych osobowych
Polityka cookies

Partnerzy